About Lilly
Lilly is a publicly listed company based in United States founded in 1876 by Eli Lilly. Traditional pharmaceutical medicines are developed for multiple health fields. The company has 47,000 employees. Lilly has completed 38 acquisitions, including 4E Therapeutics, Adverum Biotechnologies and Ajax Therapeutics. Its website lilly.com draws about 4.9 million monthly visits. Its Indian entity Eli Lilly Services India Private Limited reported revenue of ₹1,617 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.
Company details
The company was founded in 1876 in the United States by Eli Lilly and operates within the pharmaceutical sector. Traditional medicines are developed and produced across oncology, cardiovascular, diabetes, critical care, neuroscience, mens health, and musculoskeletal areas. In 2022, annual revenues of 28.54 billion were recorded, alongside a net profit of 6.24 billion. Focus remains on established drug development processes.
- Indian entity revenue₹1,617 Cr
FY 2025 · +55% YoY
- Indian entity net profit₹302 Cr
FY 2025 · 19% margin
- Indian entity EBITDA₹418 Cr
FY 2025 · 26% margin
- InvestorsMoody's
& 4 more
- Employee Count47,000
- Investments & Acquisitions4E Therapeutics
& 37 more
Associated legal entities of Lilly
Lilly operates through Eli Lilly Services India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Eli Lilly Services India Private Limited CIN U72200KA2015FTC082300 | Active | 17 Aug 2015 | Bengaluru, Karnataka | ₹1,617 Cr | 2,677 | 6 | View details |
Funding Insights of Lilly
- Total Rounds 9
- First Round $18.89M
(Jun 2007)
- Investors Count 5
All 9 funding rounds of Lilly with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | Post-IPO | – | – | ||
| Mar 2019 | $4.5B | Debt – Conventional | – | – | – |
| Aug 2018 | $358,692 | Grant | – | – | |
| May 2015 | $1.91M | Grant | – | – | |
| Oct 2014 | $469,631 | Grant | – | – | |
| Jun 2012 | Grant | – | – | ||
| Jul 2010 | $18.89M | Grant | – | – | |
| Apr 2008 | $150M | Debt – Conventional | – | – | |
| Jun 2007 | $18.89M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Lilly
Lilly has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Moody's, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Financial databases for credit ratings and analytics are maintained. | 1909 | moodys.com | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| usgs.gov |
Investor details for Lilly
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Eli Lilly Services India Private Limited (Lilly)
Eli Lilly Services India Private Limited is the primary company behind Lilly. The board of Eli Lilly Services India Private Limited currently have 6 directors; the longest-serving is Ranjeet Singh Walia, appointed in 2023. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ranjeet Singh Walia DIN 06853549 | Director | 01 Aug 2023 | 3 yrs 2 mo | Eli Lilly Services India Private Limited |
| Nandkumar Aparna DIN 10681186 | Director | 02 Jul 2024 | 2 yrs 3 mo | Eli Lilly Services India Private Limited |
| David Cotter DIN 10776768 | Managing Director | 17 Sep 2024 | 2 yrs 1 mo | Eli Lilly Services India Private Limited |
| Anjali Rao DIN 11245790 | Director | 01 Sep 2025 | 1 yr 1 mo | Eli Lilly Services India Private Limited |
| Manish Ashok Arora DIN 11247802 | Director | 01 Sep 2025 | 1 yr 1 mo | Eli Lilly Services India Private Limited |
| Alberto Sanchez Calle DIN 11251264 | Director | 01 Sep 2025 | 1 yr 1 mo | Eli Lilly Services India Private Limited |
People of Lilly
167 people are tracked at Lilly (124 in leadership, 11 in board & advisors, 32 in team); the tracked headcount is 47,000.
| Name | Role | Group |
|---|---|---|
Eli Lilly | Founder | Leadership |
Anna M Szpurka | Executive Director | Leadership |
Jessica Roberts | Sr. Director - Patent Counsel | Leadership |
Jamie Preston | Vice President HR Global Compensation | Leadership |
Ann Chen | VP - Global Brand Attorney | Leadership |
Thomas Lee | Senior Director | Leadership |
Anne White | President - Lilly Neuroscience | Leadership |
Kristen Dean | Executive Director Immunology Customer Strategy | Leadership |
Anne E. White | SVP & President, Lilly Oncology | Leadership |
Patrik Jonsson | SVP & President, Lilly Bio-Medicines | Leadership |
André Schönichen | Director, Diagnostics Development | Leadership |
Kapil Kamat | Sr. Director, Technology | Leadership |
Malika Mahoui | Associate Director- IT | Leadership |
Edgardo Hernandez | SVP & President, Manufacturing Operations | Leadership |
Sharanya Murty | Senior Director, Health Outcomes And Real World Evidence | Leadership |
Chris Anderson | Vice President, Leader Of Corporate Securities & Assistant Corp. Secretary | Leadership |
Nicholas Kunz | Senior Director - Patent Counsel, Neuroscience | Leadership |
Ben Thompson | Senior Director | Leadership |
Andrea Abell | Chief Information Security Officer | Leadership |
Jason Yazell | Sr. Director - Explor&d - AI & Automation Transformation | Leadership |
147 more people are available in the full profile.
Complete people profiles for Lilly
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lilly
Lilly is a publicly listed company on the NYSE with ticker symbol LLY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Sep 2013
- Listed onSWX: LLY
- Listed entityEli Lilly and Company
- Exchange sectorHealth technology
- ISINUS5324571083
- Share price$1,166.51 (-1.36% on the day) · 2026-10-13
- Market capitalisation$1,098.10B
- Price to earnings39.6
- EPS (diluted, trailing year)$29.43
- Dividend yield0.57%
- Volume (last session)1,843,734
Financials of Lilly
Figures of Eli Lilly Services India Private Limited, the primary company behind Lilly, for FY 2025. Revenue was ₹1,617 Cr (+55% year on year). Net profit was ₹302 Cr (19% margin). EBITDA was ₹418 Cr (26% margin). Revenue has grown at a compounded annual rate of +52% over three years and +55% over five years.
- ₹1,617 CrRevenue · FY 2025 · +55% YoY
- ₹302 CrNet profit · 19% margin
- ₹418 CrEBITDA · 26% margin
- ₹1 LakhPaid-up capital
- 2,677Employees (provident fund records)
- +52%Revenue CAGR, 3 years
- +55%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $65.18B | $20.64B | $31.69B |
| 2024 | $45.04B | $10.59B | $18.81B |
| 2023 | $34.12B | $5.24B | $11.85B |
| 2022 | $28.54B | $6.24B | $9.80B |
| 2021 | $28.32B | $5.58B | $9.10B |
Balance sheet, profit and loss, cash flow and ratios of Eli Lilly Services India Private Limited are on its company page.
Detailed financial statements for Lilly
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lilly
Lilly has strategically engaged in corporate development activities, having acquired 38 companies. Notable acquisitions include 4E Therapeutics, Adverum Biotechnologies and Ajax Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Non-opioid drugs for neuropathic pain are developed through novel mechanisms. | 4etherapeutics.com | Austin, United States | 2019 | Jun 2026 | •••• | |
Bioconjugate vaccines are developed using glycoengineering and protein glycosylation techniques. | lmtbio.com | Schlieren, Switzerland | 2015 | May 2026 | $780M | |
Developer of immunotherapies for the treatment of cancer | engagebio.com | Santa Clara, United States | 2021 | May 2026 | $202M | |
Targeted therapies for hematologic malignancies are developed. | ajaxtherapeutics.com | Cambridge, United States | 2019 | Apr 2026 | $2.3B | |
Medicines for autoimmune and inflammatory conditions are developed. | keloniatx.com | Boston, United States | 2021 | Apr 2026 | $3.25B | |
Antibody-Drug Conjugate therapeutics are developed using stable dual-linker technology. | crossbridgebio.com | Houston, United States | 2023 | Apr 2026 | •••• | |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. | centessa.com | Boston, United States | 2021 | Mar 2026 | •••• | |
Technologies for producing circular RNA therapeutics are developed. | ornatx.com | Cambridge, United States | 2020 | Feb 2026 | $2.4B | |
Therapeutics for autoimmune diseases are developed by the company. | ventyxbio.com | Encinitas, United States | 2018 | Jan 2026 | $1.2B | |
Gene therapies for ocular disorders are developed. | adverum.com | Menlo Park, United States | 2006 | Oct 2025 | •••• |
Complete acquisition details for Lilly
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lilly
14 dated milestones of Lilly across 150 years, from founding to its latest funding, stage changes and deals.
- Founded Lilly is founded.
- Funding First funding round of $18.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires Adverum Biotechnologies.
- Acquisition Acquires Ventyx Biosciences.
- Acquisition Acquires Orna.
- Acquisition Acquires Centessa Pharmaceuticals.
- Acquisition Acquires CrossBridge Bio.
- Acquisition Acquires Kelonia Therapeutics.
- Acquisition Acquires Ajax Therapeutics.
- Acquisition Acquires Engage Bio.
- Acquisition Acquires LimmaTech Biologics.
- Acquisition Acquires 4E Therapeutics.
Competitors of Lilly
Lilly has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others |
Detailed competitors of Lilly
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lilly
The website of Lilly (lilly.com) receives about 4.9M visits a month and ranks #13,252 among all websites worldwide, #260 in Health.
- Monthly visits4.9M
▲ 2.2% vs previous month
- Unique visitors2.9M
per month
- Global rank#13,252
among all websites
- Category rank#260
Health · Health
- Bounce rate57%
- Pages per visit2.5
- Average visit1 min 57 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Lilly. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gsk.com | 100% | 1.3M | #56,834 | View details | |
| abbott.com | 100% | 917.2K | #65,577 | View details | |
| bms.com | 99% | 809.8K | #67,210 | View details | |
| novonordisk.com | 91% | 637.8K | #83,485 | View details | |
comparetreatments.com | comparetreatments.com | 90% | #153,011 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Lilly
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Lilly (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lilly
Complete news archive for Lilly
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lilly
Lilly was founded in 1876 and raised its 1st funding round 131 years after it was founded.
Lilly is headquartered in United States.
Lilly has 47,000 employees.
The primary company behind Lilly, Eli Lilly Services India Private Limited, reported revenue of ₹1,617 Cr for FY 2025, up 55% year on year.
The company was founded in 1876 in the United States by Eli Lilly and operates within the pharmaceutical sector. Traditional medicines are developed and produced across oncology, cardiovascular, diabetes, critical care, neuroscience, mens health, and musculoskeletal areas. In 2022, annual revenues of 28.54 billion were recorded, alongside a net profit of 6.24 billion. Focus remains on established drug development processes.
Lilly's top competitors include Roivant Sciences, AbbVie and Gilead.
Yes, Lilly is publicly traded on NYSE under the ticker symbol LLY.
Lilly has made 38 acquisitions, including 4E Therapeutics, Adverum Biotechnologies, and Ajax Therapeutics.
Lilly has 5 investors. Key investors include Moody's, Gates Foundation, HHS, European Union, and United States Geological Survey.
Lilly operates through Eli Lilly Services India Private Limited.
The legal entities of Lilly currently have 6 directors, including Ranjeet Singh Walia, Nandkumar Aparna, David Cotter and others.
The website of Lilly receives about 4.9 million visits a month and ranks #13,252 among all websites worldwide.